Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED, savolitinib and surufatinib, will be presented at the ...

Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor ... Patients were assigned a randomization number that linked to either the remibrutinib group or the placebo group ...

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs ... Kinase activity was evaluated with the enzyme-linked immunosorbent assay (ELISA). Briefly, 20 μg/ml Poly (Glu, Tyr) 4:1 ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

The authors provide convincing evidence indicating that two receptor tyrosine kinases (RTKs), CAD96CA and FGFR1, modulate the genomic effects of JH by phosphorylating the intracellular receptors in ...

(HealthDay News) — Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose ...

This study used comprehensive analysis to evaluate Homoaromatic tyrosine (2Y, 3Y, and 4Y) peptides for their interactions with FXTAS, causing expanded CGG RNAs. Biophysical techniques were employed to ...